Ben Venue manufacturing difficulties spell delays for Clavis' Phase III CLAVELA trial
This article was originally published in Scrip
Clavis Pharma has said that the top-line results from its Phase III CLAVELA trial in patients with late-stage acute myeloid leukaemia (AML) will be delayed by three months due to a shortage of the investigational drug elacytarabine, caused by problems with its present manufacturer, Ben Venue Laboratories. The data are now expected in the first quarter of 2013.
You may also be interested in...
Danish firm Topotarget said it was 'very confident' that it will be able to raise its first milestone from partner, Spectrum Pharmaceuticals, by the third quarter as it reported that final top-line data confirm that the primary endpoint was met in the Phase II BELIEF trial investigating an intravenous formulation of the histone deacetylase (HDAC) inhibitor, belinostat, for peripheral T-cell lymphoma (PTCL).
AstraZeneca's Caprelsa (vandetanib) has become the first treatment to be approved for advanced medullary thyroid cancer (MTC) in Europe after being granted marketing authorisation by the European Commission.
Despite reporting positive weight loss data from the third of four Phase IIIa trials from the SCALE program investigating liraglutide (Victoza) for obesity Novo Nordisk has failed to dazzle analysts who have questioned the commercial potential of the drug in this arena.